Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UQC9

UPID:
CLCA2_HUMAN

ALTERNATIVE NAMES:
Calcium-activated chloride channel family member 2; Calcium-activated chloride channel protein 3

ALTERNATIVE UPACC:
Q9UQC9; A8K2T3; Q9Y6N2

BACKGROUND:
The protein Calcium-activated chloride channel regulator 2, with alternative names such as Calcium-activated chloride channel family member 2 and protein 3, is pivotal in regulating chloride current in a calcium-dependent manner and facilitating cell adhesion. It plays a key role in the stratification of squamous epithelia and may act as a tumor suppressor in specific cancers. Its function in lung metastasis initiation through ITGB4 binding underscores its importance in cancer biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calcium-activated chloride channel regulator 2 offers promising avenues for therapeutic intervention, particularly in its role as a tumor suppressor and in mediating cell adhesion processes critical for lung metastasis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.